Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
Aswolinskiy W, Munari E, Horlings HM, Mulder L, Bogina G, Sanders J, Liu YH, van den Belt-Dusebout AW, Tessier L, Balkenhol M, Stegeman M, Hoven J, Wesseling J, van der Laak J, Lips EH, Ciompi F. Aswolinskiy W, et al. Among authors: horlings hm. Breast Cancer Res. 2023 Nov 13;25(1):142. doi: 10.1186/s13058-023-01726-0. Breast Cancer Res. 2023. PMID: 37957667 Free PMC article.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. El Bairi K, et al. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. NPJ Breast Cancer. 2021. PMID: 34853355 Free PMC article. Review.
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.
Geurts VCM, Voorwerk L, Balduzzi S, Salgado R, Van de Vijver K, van Dongen MGJ, Kemper I, Mandjes IAM, Heuver M, Sparreboom W, Haanen JBAG, Sonke GS, Horlings HM, Kok M. Geurts VCM, et al. Among authors: horlings hm. Breast. 2023 Aug;70:76-81. doi: 10.1016/j.breast.2023.06.007. Epub 2023 Jun 27. Breast. 2023. PMID: 37393645 Free PMC article. Clinical Trial.
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, Yang Z, Sator-Schmitt M, Engel H, Li X, Broderick C, Jin G, Gomez-Eerland R, Rozeman L, Lei X, Matsuo H, Yang C, Hofland I, Peters D, Broeks A, Laport E, Fitz A, Zhao X, Mahmoud MAA, Ma X, Sander S, Liu HK, Cui G, Gan Y, Wu W, Xiao Y, Heck AJR, Guan W, Lowe SW, Horlings HM, Wang C, Brummelkamp TR, Blank CU, Schumacher TNM, Sun C. Miao B, et al. Among authors: horlings hm. Cancer Cell. 2023 Oct 9;41(10):1817-1828.e9. doi: 10.1016/j.ccell.2023.08.008. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683639 Free PMC article.
Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank.
Zelisse HS, van Gent MDJM, Mom CH, de Ridder S, Snijders MLH, Heeling M, Stoter M, Broeks A, Horlings HM, Lok CAR, Bosch SL, Piek JM, Bart J, Reyners AKL, Wisman GBA, Yigit R, Boere IA, Collée M, Groenendijk FH, Jansen MPHM, Roes EM, Hofhuis W, Hoogduin KJ, Alcalá LSM, Smedts HPM, Makkus ACF, Nieuwenhuyzen-de Boer GM, van Es N, Vencken PMLH, van Altena AM, Simons M, Hazelbag HM, Kagie MJ, Aliredjo R, Bonestroo TJJ, Bosse T, de Kroon CD, Brinkhuis M, Janssen MJ, Koster NC, Kruse AJ, Gerestein CG, Jonges TGN, Zweemer RP, Kooreman LFS, Lambrechts S, Ebisch IMW, de Kievit van der Heijden IM, Voorham QJ, van der Aa MA, Belien JAM, van de Vijver MJ, Dijk F; Archipelago of Ovarian Cancer Research Consortium. Zelisse HS, et al. Among authors: horlings hm. Ann Diagn Pathol. 2025 Feb;74:152411. doi: 10.1016/j.anndiagpath.2024.152411. Epub 2024 Nov 19. Ann Diagn Pathol. 2025. PMID: 39591762 Free article.
An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.
Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A, Zhou HY, Zhang T, van Duijnhoven FH, Han L, Li X, D'Angelo A, Longo V, Liu Z, Teuwen J, Kok M, Beets-Tan R, Horlings HM, Tan T, Mann R. Gao Y, et al. Among authors: horlings hm. Nat Commun. 2024 Nov 7;15(1):9613. doi: 10.1038/s41467-024-53450-8. Nat Commun. 2024. PMID: 39511143 Free PMC article.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. Nederlof I, et al. Among authors: horlings hm. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284953 Free PMC article. Clinical Trial.
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Opdam M, van Rossum AGJ, Hoogstraat M, Bounova G, Horlings HM, van Werkhoven E, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker S, Wesseling J, Kester L, van Rheenen J, Rutgers EJ, de Menezes RX, Wessels LFA, Kok M, Oosterkamp HM, Linn SC; MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG). Opdam M, et al. Among authors: horlings hm. iScience. 2024 Jun 29;27(8):110425. doi: 10.1016/j.isci.2024.110425. eCollection 2024 Aug 16. iScience. 2024. PMID: 39206149 Free PMC article.
119 results